Genomic architecture of pharmacological efficacy and adverse events

Pharmacogenomics

Volumn 15, Issue 16, 2014, Pages 2025-2048

  Chhibber, Aparna ^a   Kroetz, Deanna L ^a   Tantisira, Kelan G ^b   Mcgeachie, Michael ^b   Cheng, Cheng ^c   Plenge, Robert ^b   Stahl, Eli ^d   Sadee, Wolfgang ^e   Ritchie, Marylyn D ^f   Pendergrass, Sarah A ^f  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^d MOUNT SINAI HOSPITAL   (United States)

^e THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

^f PENNSYLVANIA STATE UNIVERSITY   (United States)

Author keywords

genetic architecture; genomics; heritability; linear mixed modeling; pharmacogenomics; polygenic architecture; polygenic modeling

Indexed keywords

ACETYLSALICYLIC ACID; AMOXICILLIN; AMPICILLIN; CAFFEINE; CISPLATIN; CLOPIDOGREL; CYCLOSPORIN; CYTARABINE; DEXTROMETHORPHAN; DICOUMAROL; DIGOXIN; DOXORUBICIN; EPIRUBICIN; ERYTHROMYCIN; ETHINYLESTRADIOL; GEMCITABINE; IOHEXOL; METFORMIN; MIDAZOLAM; NEVIRAPINE; NIFEDIPINE; NITRENDIPINE; OXAZEPAM; PHENAZONE; SIMVASTATIN; TERODILINE; TOPOTECAN; UNINDEXED DRUG; VINBLASTINE; WARFARIN;

ACUTE GRANULOCYTIC LEUKEMIA; ANCESTRY GROUP; BLEEDING; CARDIOEMBOLIC STROKE; CLINICAL DECISION MAKING; CYTOARCHITECTURE; DIZYGOTIC TWINS; DRUG CLEARANCE; DRUG HALF LIFE; DRUG METABOLISM; DRUG RESPONSE; EFFECT SIZE; EPISTASIS; GENE INTERACTION; GENE LINKAGE DISEQUILIBRIUM; GENETIC MARKER; GENETIC VARIABILITY; GENOTYPE ENVIRONMENT INTERACTION; HAPLOTYPE MAP; HEART INFARCTION; HEREDITY; HERITABILITY; HUMAN; LYMPHOBLASTOID CELL LINE; MULTIFACTORIAL INHERITANCE; MUSCLE DISEASE; PHARMACOGENOMICS; PHENOTYPE; REVIEW; RISK FACTOR; THROMBOCYTE AGGREGATION; VEIN THROMBOSIS; ADVERSE DRUG REACTION; DISEASES; DRUG THERAPY; GENETICS; GENOME-WIDE ASSOCIATION STUDY; PHARMACOGENETICS;

DISEASE; DRUG THERAPY; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; GENOME-WIDE ASSOCIATION STUDY; HUMANS; MULTIFACTORIAL INHERITANCE; PHARMACOGENETICS;

EID: 84919784551     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.14.144     Document Type: Review

References (143)

1. Green ED, Guyer MS. Charting a course for genomic medicine from base pairs to bedside. Nature 470(7333), 204-213 (2011
2. Bergmann TK, Vach W, Feddersen S, et al. GWAS-based association between RWDD3 and TECTA variants and paclitaxel induced neuropathy could not be confirmed in Scandinavian ovarian cancer patients. Acta Oncol. 52(4), 871-874 (2013
3. PGRN. www.pgrn.org/display/pgrnwebsite/PGRN+Home
4. Ofverholm A, Einbeigi Z, Manouchehrpour S, Albertsson P, Skrtic S, Enerbäck C. The ABCB1 3435 T allele does not increase the risk of paclitaxel-induced neurotoxicity. Oncol. Lett. 1(1), 151-154 (2010
5. PharmGKB. www.pharmgkb.org/
6. Maher B. Personal genomes: the case of the missing heritability. Nature 456(7218), 18-21 (2008
7. Ioannidis JPA. Biomarker Failures. Clin. Chem. 59(1), 202-204 (2013
8. Sadee W. Pharmacogenomic biomarkers: validation needed for both the molecular genetic mechanism and clinical effect. Pharmacogenomics 12(5), 675-680 (2011
9. Wilke RA, Ramsey LB, Johnson SG, et al. The clinical pharmacogenomics implementation consortium: CPIC guideline for SLCO1B1 and simvastatin-induced myopathy. Clin. Pharmacol. Ther. 92(1), 112-117 (2012
10. Shuldiner AR, OConnell JR, Bliden KP, et al. Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. JAMA 302(8), 849-857 (2009
11. Vesell ES, Page JG. Genetic control of dicumarol levels in man. J. Clin. Invest. 47(12), 2657-2663 (1968
12. Faraday N, Yanek LR, Mathias R, et al Heritability of platelet responsiveness to aspirin in activation pathways directly and indirectly related to cyclooxygenase-1. Circulation 115(19), 2490-2496 (2007
13. Stark AL, Zhang W, Mi S, et al. Heritable and non-genetic factors as variables of pharmacologic phenotypes in lymphoblastoid cell lines. Pharmacogenomics J. 10(6), 505-512 (2010
14. Dolan ME, Newbold KG, Nagasubramanian R, et al. Heritability and linkage analysis of sensitivity to cisplatin-induced cytotoxicity. Cancer Res. 64(12), 4353-4356 (2004
15. Peters EJ, Motsinger-Reif A, Havener TM, et al. Pharmacogenomic characterization of US FDA-Approved cytotoxic drugs. Pharmacogenomics 12(10), 1407-1415 (2011
16. Watters JW, Kraja A, Meucci MA, Province MA, McLeod HL. Genome-wide discovery of loci influencing chemotherapy cytotoxicity. Proc. Natl Acad. Sci. USA 101(32), 11809-11814 (2004
17. Duan S, Bleibel WK, Huang RS, et al. Mapping genes that contribute to daunorubicin-induced cytotoxicity. Cancer Res. 67(11), 5425-5433 (2007
18. Lamba JK, Crews K, Pounds S, et al. Pharmacogenetics of deoxycytidine kinase: identification and characterization of novel genetic variants. J. Pharmacol. Exp. Ther. 323(3), 935-945 (2007
19. Kalow W, Tang BK, Endrenyi L. Hypothesis: comparisons of inter-And intra-individual variations can substitute for twin studies in drug research. Pharmacogenetics. 8(4), 283-289 (1998
20. Wu AC, Tantisira K, Li L, Schuemann B, Weiss S, Childhood Asthma Management Program Research Group. Repeatability of response to asthma medications. J. Allergy Clin. Immunol. 123(2), 385-390 (2009
21. Leabman MK, Giacomini KM. Estimating the contribution of genes and environment to variation in renal drug clearance. Pharmacogenetics 13(9), 581-584 (2003
22. Pentikäinen PJ, Neuvonen PJ, Penttilä A. Pharmacokinetics of metformin after intravenous and oral administration to man. Eur. J. Clin. Pharmacol. 16(3), 195-202 (1979
23. Sjövall J, Alván G, Huitfeldt B. Intra-And inter-individual variation in pharmacokinetics of intravenously infused amoxycillin and ampicillin to elderly volunteers. Br. J. Clin. Pharmacol. 21(2), 171-181 (1986
24. Hallén B, Guilbaud O, Strömberg S, Lindeke B. Single-dose pharmacokinetics of terodiline, including a stable. isotope technique for improvement of statistical evaluations. Biopharm. Drug Dispos. 9(3), 229-250 (1988
25. Arvidsson A, Hedman A. Plasma and renal clearance of iohexol-A study on the reproducibility of a method for the glomerular filtration rate. Scand. J. Clin. Lab. Invest. 50(7), 757-761 (1990
26. Wagner JG. Inter-And intrasubject variation of digoxin renal clearance in normal adult males. Drug Intell. Clin. Pharm. 22(7-8), 562-567 (1988
27. Kalow W, Endrenyi L, Tang B. Repeat administration of drugs as a means to assess the genetic component in pharmacological variability. Pharmacology 58(6), 281-284 (1999
28. Ozdemir V, Kalow W, Tang BK, et al. Evaluation of the genetic component of variability in CYP3A4 activity: a repeated drug administration method. Pharmacogenetics 10(5), 373-388 (2000
29. Micheli JE, Chinn LW, Shugarts SB, et al. Measuring the overall genetic component of nevirapine pharmacokinetics and the role of selected polymorphisms: towards addressing the missing heritability in pharmacogenetic phenotypes?. Pharmacogenet. Genomics 23(11), 591-596 (2013
30. Birkenfeld AL, Jordan J, Hofmann U, et al. Genetic influences on the pharmacokinetics of orally and intravenously administered digoxin as exhibited by monozygotic twins. Clin. Pharmacol. Ther. 86(6), 605-608 (2009
31. Kroetz DL, Nguyen T, Giang T, et al. Heritability of digoxin pharmacokinetics. Clin. Pharmacol. Ther. 77(2), P21-P21 (2005
32. Leabman M, Brown C, Chung J, et al. Heritability of metformin renal clearance. Clin. Pharmacol. Ther. 77(2), P61-P61 (2005
33. Gage BF, Lesko LJ. Pharmacogenetics of warfarin: regulatory, scientific, and clinical issues. J. Thromb. Thrombolysis 25(1), 45-51 (2008
34. Schwarz UI, Ritchie MD, Bradford Y, et al. Genetic determinants of response to warfarin during initial anticoagulation. N. Engl. J. Med. 358(10), 999-1008 (2008
35. Taube J, Halsall D, Baglin T. Influence of cytochrome P-450 CYP2C9 polymorphisms on warfarin sensitivity and risk of over-Anticoagulation in patients on long-Term treatment. Blood 96(5), 1816-1819 (2000
36. Rost S, Fregin A, Ivaskevicius V, et al Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2. Nature 427(6974), 537-541 (2004
37. Rieder MJ, Reiner AP, Gage BF, et al. Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N. Engl. J. Med. 352(22), 2285-2293 (2005
38. Scott SA, Edelmann L, Kornreich R, Desnick RJ. Warfarin pharmacogenetics: CYP2C9 and VKORC1 genotypes predict different sensitivity and resistance frequencies in the Ashkenazi and Sephardi Jewish populations. Am. J. Hum. Genet. 82(2), 495-500 (2008
39. Veenstra DL, You JHS, Rieder MJ, et al. Association of Vitamin K epoxide reductase complex 1 (VKORC1) variants with warfarin dose in a Hong Kong Chinese patient population. Pharmacogenet. Genomics 15(10), 687-691 (2005
40. International Warfarin Pharmacogenetics Consortium, Klein TE, Altman RB, et al. Estimation of the warfarin dose with clinical and pharmacogenetic data. N. Engl. J. Med. 360(8), 753-764 (2009
41. Kimmel SE, French B, Kasner SE, et al. A pharmacogenetic versus a clinical algorithm for warfarin dosing. N. Engl. J. Med. 369(24), 2283-2293 (2013
42. Pirmohamed M, Burnside G, Eriksson N, et al. A randomized trial of genotype-guided dosing of warfarin. N. Engl. J. Med. 369(24), 2294-2303 (2013
43. Scott SA, Sangkuhl K, Gardner EE, et al. Clinical pharmacogenetics implementation consortium guidelines for cytochrome P450-2C19 (CYP2C19) genotype and clopidogrel therapy. Clin. Pharmacol. Ther. 90(2), 328-332 (2011
44. Collet J-P, Hulot J-S, Pena A, et al. Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study. Lancet 373(9660), 309-317 (2009
45. Table of Pharmacogenomic Biomarkers in Drug Labeling. www.fda.gov/drugs/scienceresearch/researchareas/pharmacogenetics/ucm083378.htm
46. Relling MV, Klein TE. CPIC: Clinical Pharmacogenetics Implementation Consortium of the Pharmacogenomics Research Network. Clin. Pharmacol. Ther. 89(3), 464-467 (2011
47. Swen JJ, Nijenhuis M, de Boer A, et al. Pharmacogenetics: from bench to byte-An update of guidelines. Clin. Pharmacol. Ther. 89(5), 662-673 (2011
48. PharmGKB: Dosing Guidelines-CPIC. www.pharmgkb.org/view/dosing-guidelines. do?source=CPIC
49. PharmGKB: CPIC pairs. www.pharmgkb.org/page/cpicGeneDrugPairs
50. TPMT nomenclature committee. www.imh.liu.se/tpmtalleles
51. PharmGKB: TPMT. www.pharmgkb.org/gene/PA356#tabview=tab4&subtab=31
52. Relling MV, Gardner EE, Sandborn WJ, et al. Clinical Pharmacogenetics Implementation Consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosing. Clin. Pharmacol. Ther. 89(3), 387-391 (2011
53. CYP2C19 allele nomenclature. www.cypalleles.ki.se/cyp2c19.htm
54. Scott SA, Sangkuhl K, Stein CM, et al. Clinical Pharmacogenetics Implementation Consortium guidelines for CYP2C19 genotype and clopidogrel therapy: 2013 update. Clin. Pharmacol. Ther. 94(3), 317-323 (2013
55. Johnson JA, Gong L, Whirl-Carrillo M, et al. Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C9 and VKORC1 genotypes and warfarin dosing. Clin. Pharmacol. Ther. 90(4), 625-629 (2011
56. The Human Cytochrome P450 (CYP) Allele Nomenclature Database. www.cypalleles.ki.se
57. Crews KR, Gaedigk A, Dunnenberger HM, et al. Clinical Pharmacogenetics Implementation Consortium Guidelines for Cytochrome P450 2D6 Genotype and Codeine Therapy: 2014 Update. Clin. Pharmacol. Ther. 95(4), 376-382 (2014
58. Martin MA, Hoffman JM, Freimuth RR, et al. Clinical Pharmacogenetics Implementation Consortium Guidelines for HLA-B Genotype and Abacavir Dosing: 2014 Update. Clin. Pharmacol. Ther. 95(5), 499-500 (2014
59. Hershfield MS, Callaghan JT, Tassaneeyakul W, et al. Clinical Pharmacogenetics Implementation Consortium guidelines for human leukocyte antigen-B genotype and allopurinol dosing. Clin. Pharmacol. Ther. 93(2), 153-158 (2013
60. Hicks JK, Swen JJ, Thorn CF, et al. Clinical Pharmacogenetics Implementation Consortium guideline for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants. Clin. Pharmacol. Ther. 93(5), 402-408 (2013
61. Leckband SG, Kelsoe JR, Dunnenberger HM, et al. Clinical Pharmacogenetics Implementation Consortium guidelines for HLA-B genotype and carbamazepine dosing. Clin. Pharmacol. Ther. 94(3), 324-328 (2013
62. Caudle KE, Thorn CF, Klein TE, et al. Clinical Pharmacogenetics Implementation Consortium guidelines for dihydropyrimidine dehydrogenase genotype and fluoropyrimidine dosing. Clin. Pharmacol. Ther. 94(6), 640-645 (2013
63. Muir AJ, Gong L, Johnson SG, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for IFNL3 (IL28B) genotype and PEG interferon-A-based regimens. Clin. Pharmacol. Ther. 95(2), 141-146 (2014
64. Clancy JP, Johnson SG, Yee SW, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for ivacaftor therapy in the context of CFTR genotype. Clin. Pharmacol. Ther. (2014
65. Hindorff LA, Sethupathy P, Junkins HA, et al. Potential etiologic and functional implications of genome-wide association loci for human diseases and traits. Proc. Natl Acad. Sci. USA 106(23), 9362-9367 (2009
66. Zhou S-F. Polymorphism of human cytochrome P450 2D6 and its clinical significance: Part I. Clin. Pharmacokinet. 48(11), 689-723 (2009
67. Thorn CF, Klein TE, Altman RB. PharmGKB: The Pharmacogenomics Knowledge Base. Methods Mol. Biol. 1015, 311-320 (2013
68. Wang D, Poi MJ, Sun X, Gaedigk A, Leeder JS, Sadee W. Common CYP2D6 polymorphisms affecting alternative splicing and transcription: long-range haplotypes with two regulatory variants modulate CYP2D6 activity. Hum. Mol. Genet. 23(1), 268-278 (2014
69. Daly AK. Genome-wide association studies in pharmacogenomics. Nat. Rev. Genet. 11(4), 241-246 (2010
70. Daly AK. Pharmacogenomics of adverse drug reactions. Genome Med. 5(1), 5 (2013
71. Pompeu YA, Stewart JD, Mallal S, Phillips E, Peters B, Ostrov DA. The structural basis of HLA-Associated drug hypersensitivity syndromes. Immunol. Rev. 250(1), 158-166 (2012
72. Sadee W, Wang D, Papp AC, et al. Pharmacogenomics of the RNA world: structural RNA polymorphisms in drug therapy. Clin. Pharmacol. Ther. 89(3), 355-365 (2011
73. ENCODE Project Consortium. A users guide to the encyclopedia of DNA elements (ENCODE). PLoS Biol. 9(4), e1001046 (2011
74. Ward LD, Kellis M. HaploReg: a resource for exploring chromatin states, conservation, and regulatory motif alterations within sets of genetically linked variants. Nucl. Acids Res. 40(Database issue), D930-D934 (2011
75. Boyle AP, Hong EL, Hariharan M, et al. Annotation of functional variation in personal genomes using RegulomeDB. Genome Res. 22(9), 1790-1797 (2012
76. Gamazon ER, Zhang W, Konkashbaev A, et al. SCAN: SNP and copy number annotation. Bioinformatics 26(2), 259-262 (2010
77. Yang J, Lee SH, Goddard ME, Visscher PM. GCTA: a tool for genome-wide complex trait analysis. Am. J. Hum. Genet. 88(1), 76-82 (2011
78. Yang J, Benyamin B, McEvoy BP, et al. Common SNPs explain a large proportion of the heritability for human height. Nat. Genet. 42(7), 565-569 (2010
79. Lee SH, Wray NR, Goddard ME, Visscher PM. Estimating missing heritability for disease from genome-wide association studies. Am. J. Hum. Genet. 88(3), 294-305 (2011
80. Yang J, Manolio TA, Pasquale LR, et al. Genome partitioning of genetic variation for complex traits using common SNPs. Nat. Genet. 43(6), 519-525 (2011
81. Yang J, Ferreira T, Morris AP, et al. Conditional and joint multiple-SNP analysis of GWAS summary statistics identifies additional variants influencing complex traits. Nat. Genet. 44(4), 369-375, S1-S3 (2012
82. Purcell SM, Wray NR, Stone JL, et al. Common polygenic variation contributes to risk of schizophrenia and bipolar disorder. Nature 460(7256), 748-752 (2009
83. Bush WS, Sawcer SJ, de Jager PL, et al. Evidence for polygenic susceptibility to multiple sclerosis-The shape of things to come. Am. J. Hum. Genet. 86(4), 621-625 (2010
84. Lango Allen H, Estrada K, Lettre G, et al. Hundreds of variants clustered in genomic loci and biological pathways affect human height. Nature 467(7317), 832-838 (2010
85. Speliotes EK, Willer CJ, Berndt SI, et al. Association analyses of 249, 796 individuals reveal 18 new loci associated with body mass index. Nat. Genet. 42(11), 937-948 (2010
86. Stahl EA, Wegmann D, Trynka G, et al. Bayesian inference analyses of the polygenic architecture of rheumatoid arthritis. Nat. Genet. 44(5), 483-489 (2012
87. McGeachie MJ, Stahl EA, Himes BE, et al. Polygenic heritability estimates in pharmacogenetics: focus on asthma and related phenotypes. Pharmacogenet. Genomics 23(6), 324-328 (2013
88. Chhibber A, Mefford J, Stahl EA, et al. Polygenic inheritance of paclitaxel-induced sensory peripheral neuropathy driven by axon outgrowth gene sets in CALGB 40101 (Alliance). Pharmacogenomics J. 14(4), 336-342 (2014
89. Bergmann TK, Gréen H, Brasch-Andersen C, et al. Retrospective study of the impact of pharmacogenetic variants on paclitaxel toxicity and survival in patients with ovarian cancer. Eur. J. Clin. Pharmacol. 67(7), 693-700 (2011
90. De Graan A-JM, Elens L, Sprowl JA, et al. CYP3A4 22 genotype and systemic exposure affect paclitaxel-induced neurotoxicity. Clin. Cancer Res. 19(12), 3316-3324 (2013
91. Wang D, Guo Y, Wrighton SA, Cooke GE, Sadee W. Intronic polymorphism in CYP3A4 affects hepatic expression and response to statin drugs. Pharmacogenomics J. 11(4), 274-286 (2011
92. Baldwin RM, Owzar K, Zembutsu H, et al. A genome-wide association study identifies novel loci for paclitaxel-induced sensory peripheral neuropathy in CALGB 40101. Clin. Cancer Res. 18(18), 5099-5109 (2012
93. Rijcken B, Schouten JP, Weiss ST, Rosner B, De Vries K, Van der Lende R. Long-Term variability of bronchial responsiveness to histamine in a random population sample of adults. Am. Rev. Respir. Dis. 148(4 Pt 1), 944-949 (1993
94. Moffatt MF, Gut IG, Demenais F, et al. A large-scale, consortium-based genomewide association study of asthma. N. Engl. J. Med. 363(13), 1211-1221 (2010
95. Thomsen SF, van der Sluis S, Kyvik KO, Skytthe A, Backer V. Estimates of asthma heritability in a large twin sample. Clin. Exp. Allergy 40(7), 1054-1061 (2010
96. Van Dijk EL, Auger H, Jaszczyszyn Y, Thermes C. Ten years of next-generation sequencing technology. Trends Genet. 30(9), 418-426 (2014
97. Khatri P, Sirota M, Butte AJ. Ten Years of Pathway Analysis: Current Approaches and Outstanding Challenges. PLoS Comput. Biol. 8(2), e1002375 (2012
98. Petersen A, Spratt J, Tintle NL. Incorporating prior knowledge to increase the power of genome-wide association studies. In: Genome-Wide Association Studies and Genomic Prediction. Gondro C, van der Werf J, Hayes B (Eds). Humana Press, NJ, USA, 519-541 (2013
99. Worthey EA. Analysis and annotation of whole-genome or whole-exome sequencing-derived variants for clinical diagnosis. Curr. Protoc. Hum. Genet. 79, Unit 9.24 (2013
100. Wagner MJ. Rare-variant genome-wide association studies: a new frontier in genetic analysis of complex traits. Pharmacogenomics 14(4), 413-424 (2013
101. Cordell HJ. Genome-wide association studies: detecting gene-gene interactions that underlie human diseases. Nat. Rev. Genet.10(6), 392-404 (2009
102. Yaspan BL, Bush WS, Torstenson ES, et al. Genetic analysis of biological pathway data through genomic randomization. Hum. Genet. 129(5), 563-571 (2011
103. Pendergrass SA, Frase A, Wallace J, et al. Genomic analyses with biofilter 2.0: knowledge driven filtering, annotation, and model development. BioData Min. 6(1), 25 (2013
104. Bush WS, Dudek SM, Ritchie MD. Biofilter: a knowledge-integration system for the multi-locus analysis of genome-wide association studies. Pac. Symp. Biocomput., 368-379 (2009
105. Ramsey LB, Bruun GH, Yang W, et al. Rare versus common variants in pharmacogenetics: SLCO1B1 variation and methotrexate disposition. Genome Res. 22(1), 1-8 (2012
106. Bhatia G, Bansal V, Harismendy O, et al. A covering method for detecting genetic associations between rare variants and common phenotypes. PLoS Comput. Biol. 6(10), e1000954 (2010
107. Morgenthaler S, Thilly WG. A strategy to discover genes that carry multi-Allelic or mono-Allelic risk for common diseases: a cohort allelic sums test (CAST). Mutat. Res. 615(1-2), 28-56 (2007
108. Li B, Leal SM. Methods for detecting associations with rare variants for common diseases: application to analysis of sequence data. Am. J. Hum. Genet. 83(3), 311-321 (2008
109. Madsen BE, Browning SR. A groupwise association test for rare mutations using a weighted sum statistic. PLoS Genet. 5(2), e1000384 (2009
110. Han F, Pan W. A data-Adaptive sum test for disease association with multiple common or rare variants. Hum. Hered. 70(1), 42-54 (2010
111. Price AL, Kryukov GV, de Bakker PIW, et al. Pooled association tests for rare variants in exon-resequencing studies. Am. J. Hum. Genet. 86(6), 832-838 (2010
112. Hoffmann TJ, Marini NJ, Witte JS. Comprehensive approach to analyzing rare genetic variants. PLoS ONE 5(11), e13584 (2010
113. Wu MC, Lee S, Cai T, Li Y, Boehnke M, Lin X. Rare-variant association testing for sequencing data with the sequence kernel association test. Am. J. Hum. Genet. 89(1), 82-93 (2011
114. Yandell M, Huff C, Hu H, et al. A probabilistic disease-gene finder for personal genomes. Genome Res. 21(9), 1529-1542 (2011
115. Moore CB, Wallace JR, Frase AT, Pendergrass SA, Ritchie MD. BioBin: a bioinformatics tool for automating the binning of rare variants using publicly available biological knowledge. BMC Med. Genomics 6(Suppl. 2), S6 (2013
116. Moore CB, Wallace JR, Wolfe DJ, et al. Low frequency variants, collapsed based on biological knowledge, uncover complexity of population stratification in 1000 genomes project data. PLoS Genet. 9(12), e1003959 (2013
117. Moore CB, Wallace JR, Frase AT, Pendergrass SA, Ritchie MD. Using biobin to explore rare variant population stratification. Pac. Symp. Biocomput. 332-343 (2013
118. Sadee W. The relevance of "missing heritability" in pharmacogenomics. Clin. Pharmacol. Ther. 92(4), 428-430 (2012
119. Evans WE, Relling MV. Pharmacogenomics: translating functional genomics into rational therapeutics. Science 286(5439), 487-491 (1999
120. Sullivan D, Pinsonneault JK, Papp AC, et al. Dopamine transporter DAT and receptor DRD2 variants affect risk of lethal cocaine abuse: a gene-gene-environment interaction. Transl. Psychiatry 3, e222 (2013
121. Holzinger ER, Dudek SM, Frase AT, Krauss RM, Medina MW, Ritchie MD. Athena: a tool for meta-dimensional analysis applied to genotypes and gene expression data to predict hdl cholesterol levels. Pac. Symp. Biocomput. 385-396 (2013
122. Holzinger ER, Buchanan CC, Dudek SM, Torstenson EC, Turner SD, Ritchie MD. Initialization parameter sweep in ATHENA: optimizing neural networks for detecting gene-gene interactions in the presence of small main effects. Genet. Evol. Comput. Conf. 12, 203-210 (2010
123. Chen P, Lin J-J, Lu C-S, et al. Carbamazepine-induced toxic effects and HLA-B 1502 screening in Taiwan. N. Engl. J. Med. 364(12), 1126-1133 (2011
124. Man CBL, Kwan P, Baum L, et al. Association between HLA-B 1502 allele and antiepileptic drug-induced cutaneous reactions in Han Chinese. Epilepsia 48(5), 1015-1018 (2007
125. Hung S-I, Chung W-H, Liu Z-S, et al. Common risk allele in aromatic antiepileptic-drug induced Stevens-Johnson syndrome and toxic epidermal necrolysis in Han Chinese. Pharmacogenomics 11(3), 349-356 (2010
126. Locharernkul C, Loplumlert J, Limotai C, et al. Carbamazepine and phenytoin induced Stevens-Johnson syndrome is associated with HLA-B 1502 allele in Thai population. Epilepsia 49(12), 2087-2091 (2008
127. Alfirevic A, Jorgensen AL, Williamson PR, Chadwick DW, Park BK, Pirmohamed M. HLA-B locus in Caucasian patients with carbamazepine hypersensitivity. Pharmacogenomics 7(6), 813-818 (2006
128. Lonjou C, Thomas L, Borot N, et al. A marker for Stevens-Johnson syndrome: ethnicity matters. Pharmacogenomics J. 6(4), 265-268 (2006
129. Choudhry S, Ung N, Avila PC, et al. Pharmacogenetic differences in response to albuterol between Puerto Ricans and Mexicans with asthma. Am. J. Respir. Crit. Care Med. 171(6), 563-570 (2005
130. Limdi N, Goldstein J, Blaisdell J, Beasley T, Rivers C, Acton R. Influence of CYP2C9 genotype on warfarin dose among African American and European Americans. Per. Med. 4(2), 157-169 (2007
131. Scott SA, Jaremko M, Lubitz SA, Kornreich R, Halperin JL, Desnick RJ. CYP2C9 8 is prevalent among African-Americans: implications for pharmacogenetic dosing. Pharmacogenomics 10(8), 1243-1255 (2009
132. Tai G, Farin F, Rieder MJ, et al. In-vitro and in-vivo effects of the CYP2C9 11 polymorphism on warfarin metabolism and dose. Pharmacogenet. Genomics 15(7), 475-481 (2005
133. Redman AR, Dickmann LJ, Kidd RS, Goldstein JA, Ritchie DM, Hon YY. CYP2C9 genetic polymorphisms and warfarin. Clin. Appl. Thromb. Hemost. 10(2), 149-154 (2004
134. Cavallari LH, Langaee TY, Momary KM, et al. Genetic and clinical predictors of warfarin dose requirements in African Americans. Clin. Pharmacol. Ther. 87(4), 459-464 (2010
135. Wadelius M, Chen LY, Lindh JD, et al. The largest prospective warfarin-Treated cohort supports genetic forecasting. Blood 113(4), 784-792 (2009
136. Gage BF, Eby C, Johnson JA, et al. Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin. Clin. Pharmacol. Ther. 84(3), 326-331 (2008
137. Limdi NA, Wadelius M, Cavallari L, et al. Warfarin pharmacogenetics: a single VKORC1 polymorphism is predictive of dose across 3 racial groups. Blood 115(18), 3827-3834 (2010
138. Suarez-Kurtz G, Botton MR. Pharmacogenomics of warfarin in populations of African descent. Br. J. Clin. Pharmacol. 75(2), 334-346 (2013
139. Kastbom A, Bratt J, Ernestam S, et al. Fcgamma receptor type IIIA genotype and response to tumor necrosis factor alpha-blocking agents in patients with rheumatoid arthritis. Arthritis Rheum. 56(2), 448-452 (2007
140. Tutuncu Z, Kavanaugh A, Zvaifler N, Corr M, Deutsch R, Boyle D. Fcgamma receptor type IIIA polymorphisms influence treatment outcomes in patients with inflammatory arthritis treated with tumor necrosis factor alpha-blocking agents. Arthritis Rheum. 52(9), 2693-2696 (2005
141. Cañete JD, Suárez B, Hernández MV, et al. Influence of variants of Fc gamma receptors IIA and IIIA on the American College of Rheumatology and European League Against Rheumatism responses to anti-Tumour necrosis factor alpha therapy in rheumatoid arthritis. Ann. Rheum. Dis. 68(10), 1547-1552 (2009
142. Walker DM, Gore AC. Transgenerational neuroendocrine disruption of reproduction. Nat. Rev. Endocrinol. 7(4), 197-207 (2011
143. Gottesman O, Kuivaniemi H, Tromp G, et al. The Electronic Medical Records and Genomics (eMERGE) Network: past, present, and future. Genet. Med. 15(10), 761-771 (2013